SAB Biotherapeutics (SABS) Competitors $2.79 +0.25 (+9.84%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$2.68 -0.11 (-3.94%) As of 08:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SABS vs. FBIO, CRIS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. SAB Biotherapeutics vs. Its Competitors Fortress Biotech Curis Bolt Biotherapeutics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen SAB Biotherapeutics (NASDAQ:SABS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations. Which has higher earnings & valuation, SABS or FBIO? SAB Biotherapeutics has higher earnings, but lower revenue than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSAB BiotherapeuticsN/AN/A-$34.10M-$3.70-0.75Fortress Biotech$57.67M1.01-$46M-$2.23-0.88 Do institutionals and insiders believe in SABS or FBIO? 7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 27.8% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 27.9% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate SABS or FBIO? SAB Biotherapeutics currently has a consensus target price of $13.25, indicating a potential upside of 374.91%. Fortress Biotech has a consensus target price of $21.00, indicating a potential upside of 965.99%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor SABS or FBIO? In the previous week, Fortress Biotech had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 3 mentions for Fortress Biotech and 1 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.87 beat Fortress Biotech's score of 1.01 indicating that SAB Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment SAB Biotherapeutics Very Positive Fortress Biotech Positive Which has more volatility & risk, SABS or FBIO? SAB Biotherapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Is SABS or FBIO more profitable? SAB Biotherapeutics has a net margin of 0.00% compared to Fortress Biotech's net margin of -71.24%. SAB Biotherapeutics' return on equity of -105.14% beat Fortress Biotech's return on equity.Company Net Margins Return on Equity Return on Assets SAB BiotherapeuticsN/A -105.14% -69.24% Fortress Biotech -71.24%-4,712.53%-27.67% SummaryFortress Biotech beats SAB Biotherapeutics on 8 of the 14 factors compared between the two stocks. Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SABS vs. The Competition Export to ExcelMetricSAB BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.92M$2.91B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.7520.3628.1819.72Price / SalesN/A290.30439.19110.06Price / CashN/A42.3835.5357.53Price / Book0.997.768.235.67Net Income-$34.10M-$55.11M$3.23B$257.51M7 Day Performance11.60%0.19%-0.61%-0.16%1 Month Performance56.74%10.80%6.63%9.89%1 Year Performance-4.45%-0.68%27.07%15.08% SAB Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SABSSAB Biotherapeutics3.7279 of 5 stars$2.79+9.8%$13.25+374.9%-9.7%$25.92MN/A-0.75140FBIOFortress Biotech2.5341 of 5 stars$1.91+1.6%$21.00+999.5%-3.0%$55.59M$57.67M-0.86170Positive NewsCRISCuris2.5785 of 5 stars$1.74-3.9%$17.00+877.0%-73.8%$18.94M$11.20M-0.2860Positive NewsHigh Trading VolumeBOLTBolt Biotherapeutics2.5575 of 5 stars$5.87-0.8%$50.00+751.8%-61.7%$11.35M$7.69M-0.1890Positive NewsHigh Trading VolumeMTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260AMGNAmgen4.3971 of 5 stars$292.95-1.8%$307.82+5.1%-10.2%$160.37B$33.42B26.7328,000Positive NewsAnalyst RevisionGILDGilead Sciences4.8922 of 5 stars$111.78+0.0%$111.38-0.4%+53.3%$139.01B$28.75B23.5317,600Trending NewsInsider TradeOptions VolumeAnalyst RevisionVRTXVertex Pharmaceuticals4.291 of 5 stars$459.410.0%$511.62+11.4%-4.0%$118.03B$11.02B-117.206,100Trending NewsAnalyst ForecastAnalyst RevisionREGNRegeneron Pharmaceuticals4.813 of 5 stars$538.11-1.7%$813.57+51.2%-50.0%$59.10B$14.09B13.7015,106ALNYAlnylam Pharmaceuticals4.02 of 5 stars$324.13-2.3%$341.91+5.5%+29.2%$43.28B$2.25B-155.092,230Trending NewsAnalyst ForecastAnalyst RevisionBIIBBiogen4.9049 of 5 stars$130.13-2.1%$188.48+44.8%-42.9%$19.47B$9.68B12.857,605Trending NewsInsider TradeAnalyst Revision Related Companies and Tools Related Companies FBIO Competitors CRIS Competitors BOLT Competitors MTEM Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SABS) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SABS Stock Alerts